{
    "cancer_info": {
        "cancer_name": "Chronic Myeloid Leukemia"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "CBC with differential",
            "Peripheral blood smear",
            "Bone marrow aspirate/biopsy (morphology and cytogenetics)",
            "Quantitative RT-PCR (qPCR) for BCR-ABL1 transcripts (International Scale)",
            "Fluorescence in situ hybridization (FISH) for BCR-ABL1",
            "Hepatitis B panel",
            "Mutation analysis for atypical BCR-ABL1 transcripts (e.g., e1a2, e19a2)",
            "Spleen size measurement (palpation)",
            "Flow cytometry (for suspected blast phase)",
            "HLA typing (if transplant considered)",
            "Next-generation sequencing (NGS) for myeloid mutations",
            "Cerebrospinal Fluid (CSF) analysis (for CNS involvement)",
            "CT/MRI imaging (for extramedullary disease)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Chronic Phase (CP)",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Low risk (Sokal ≤0.8; ELTS ≤1.5680)",
                    "plan_name": "Imatinib",
                    "plan_details": "400 mg once daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Low risk (Sokal ≤0.8; ELTS ≤1.5680)",
                    "plan_name": "Asciminib",
                    "plan_details": "80 mg once daily or 40 mg twice daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Chronic Phase (CP)",
            "risk_group": "Intermediate risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Intermediate risk (Sokal >0.8–1.2; ELTS >1.5680–2.2185)",
                    "plan_name": "Bosutinib",
                    "plan_details": "400 mg once daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Intermediate risk (Sokal >0.8–1.2; ELTS >1.5680–2.2185)",
                    "plan_name": "Dasatinib",
                    "plan_details": "100 mg once daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Intermediate risk (Sokal >0.8–1.2; ELTS >1.5680–2.2185)",
                    "plan_name": "Nilotinib",
                    "plan_details": "300 mg twice daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Intermediate risk (Sokal >0.8–1.2; ELTS >1.5680–2.2185)",
                    "plan_name": "Asciminib",
                    "plan_details": "80 mg once daily or 40 mg twice daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Chronic Phase (CP)",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "High risk (Sokal >1.2; ELTS >2.2185)",
                    "plan_name": "Bosutinib",
                    "plan_details": "400 mg once daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "High risk (Sokal >1.2; ELTS >2.2185)",
                    "plan_name": "Dasatinib",
                    "plan_details": "100 mg once daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "High risk (Sokal >1.2; ELTS >2.2185)",
                    "plan_name": "Nilotinib",
                    "plan_details": "300 mg twice daily",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "High risk (Sokal >1.2; ELTS >2.2185)",
                    "plan_name": "Asciminib",
                    "plan_details": "80 mg once daily or 40 mg twice daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Chronic Phase (CP)",
            "risk_group": "Resistance or intolerance to first-line TKI",
            "treatment_plans": [
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "Without T315I mutation",
                    "plan_name": "Alternate TKI",
                    "plan_details": "Switch to bosutinib, dasatinib, nilotinib, ponatinib, or asciminib",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                },
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "With T315I mutation",
                    "plan_name": "Ponatinib or Asciminib",
                    "plan_details": "Ponatinib: 45 mg once daily (reduce to 15 mg upon BCR-ABL1 ≤1% IS) OR Asciminib: 200 mg twice daily",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                },
                {
                    "treatment_line": "Second-line therapy",
                    "patient_subgroup": "With specific mutations (e.g., V299L, Y253H, E255K/V)",
                    "plan_name": "Mutation-adapted TKI",
                    "plan_details": "Avoid dasatinib for V299L; avoid nilotinib for Y253H/E255K/V; select alternative TKI",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended regimen"
                }
            ]
        },
        {
            "staging_criteria": "Accelerated Phase (AP)",
            "risk_group": "Any",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Any",
                    "plan_name": "Second/third-generation TKI or asciminib",
                    "plan_details": "Bosutinib, dasatinib, nilotinib, ponatinib, or asciminib; consider allogeneic HCT if responsive",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Blast Phase (BP)",
            "risk_group": "Lymphoid",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Lymphoid blast crisis",
                    "plan_name": "ALL-type induction + TKI",
                    "plan_details": "Hyper-CVAD regimen + TKI (dasatinib or ponatinib) with CNS prophylaxis",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        },
        {
            "staging_criteria": "Blast Phase (BP)",
            "risk_group": "Myeloid",
            "treatment_plans": [
                {
                    "treatment_line": "First-line therapy",
                    "patient_subgroup": "Myeloid blast crisis",
                    "plan_name": "AML-type induction + TKI",
                    "plan_details": "Idarubicin/cytarabine or mitoxantrone/etoposide/cytarabine + TKI (dasatinib or ponatinib)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred regimen"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "e14a2 transcript variant: Predicts better response to imatinib",
            "e1a2 (p190) transcript variant: Predicts higher progression risk and inferior TKI response",
            "T315I mutation: Confers resistance to all TKIs except ponatinib and asciminib",
            "Compound mutations: Confer high resistance to ponatinib",
            "V299L mutation: Confers resistance to dasatinib",
            "Y253H, E255K/V mutations: Confer resistance to nilotinib",
            "F317L mutation: Confers resistance to dasatinib",
            "ASXL1 mutation: Predicts inferior response to TKIs",
            "IKZF1, RUNX1, DNMT3A mutations: Predict progression to accelerated/blast phase",
            "Major route ACAs (trisomy 8, isochromosome 17q): Worsen prognosis in Ph+ cells",
            "Monosomy 7/del7q: Predicts transformation to MDS/AML"
        ]
    },
    "guideline_id": "（2025.V3）NCCN临床实践指南：慢性髓性白血病.txt"
}